Answers are grounded in this paper and cite their sources.
Narrative review demonstrates the therapeutic potential of lipid-polymer hybrid nanoparticles in geriatric oncology, highlighting improved drug delivery and reduced toxicity for older adults.
Aging is accompanied by a multitude of physiological changes that significantly impact drug pharmacokinetics and dynamics, posing unique challenges in cancer treatment. Developments in nanotechnology have been crucial to fight against cancer. Lipid polymer hybrid nanoparticles have emerged as a novel nanomedicine platform designed to enhance the efficacy and safety of chemotherapeutic agents, particularly in the aging population. The adoption of nanostructures and their uses in clinical development to enhance and boost the pharmacokinetic and pharmacodynamics characteristics of medicinal substances have also been documented. Liposomes and nanoparticles are extensively utilized in cancer therapy, but are associated with multifaceted drawbacks such as high instability, quick drug release, low biocompatibility, limited drug loading capacity, and unsuitability for large-scale manufacturing. Lipid polymer hybrid nanoparticles, which combine the benefits of lipid- and polymer-based nanocarriers, have been created to get around these restrictions. Additionally, lipid polymer hybrid nanoparticles are now used for combinatorial and active targeted drug delivery, as well as the delivery of genetic materials, diagnostic imaging agents, and vaccines in addition to single drug delivery for anticancer therapy. This narrative review provides an in-depth analysis of the structural elucidation, classification, preparation process, and use of lipid polymer hybrid nanoparticles in cancer treatment and drug delivery in older patients.
No takes yet. Share an insight, caveat, or question.
Majeed et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: